Company description

Delcath Systems, Inc. (ticker symbol DCTH) is an innovative medical technology company that specializes in cancer treatment. Founded in 1988, the company is committed to improving the lives of cancer patients by providing innovative, minimally invasive treatment options. DCTH's main focus is on developing and commercializing its proprietary, precision-targeted technology, known as the Delcath Hepatic Delivery System (PHP). This technology allows for the isolation of organs and the delivery of high doses of chemotherapy and other therapeutic agents directly to the affected area, minimizing side effects and improving treatment outcomes. DCTH is also involved in ongoing clinical trials, seeking to expand the application of PHP to other types of cancer. In addition to its groundbreaking technology, the company also offers a specialized training program for physicians and other healthcare professionals to ensure proper usage and optimal patient outcomes. DCTH is committed to maintaining high ethical standards and has received multiple awards for its corporate responsibility and philanthropic efforts. With a strong dedication to advancing cancer treatment and a highly experienced team, DCTH is poised to make a significant impact in the medical field and improve the lives of cancer patients worldwide.